Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2
about
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteratureEverolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patientsPreclinical validation of a novel compound targeting p70S6 kinase in breast cancer.Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.The therapeutic potential of mTOR inhibitors in breast cancer.Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.Long-term complete response in a breast cancer patient with skeletal muscle metastases diagnosed using 18F-FDG-PETCommunity pharmacist-led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer.Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock.Bone-Targeted Therapies in Cancer-Induced Bone Disease.Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.Raptor mediates the antiproliferation of cardamonin by mTORC1 inhibition in SKOV3 cells.Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
P2860
Q26766244-372CBAFF-6D1C-43CE-8A25-EA35642DD887Q35807838-A74B1DC5-C141-4ADA-91FA-7554D025A123Q36288939-F7657441-EF79-44FA-8705-C03DC79CB9FAQ37062488-631AFD79-F488-4F66-9006-1CBC72387E74Q38602947-4C1B6EBD-EFD1-453D-A903-95F8E4B9BDF6Q38690803-3858ACFE-0FE3-4944-B202-D88BF4CE22C0Q38784119-377FC840-9CFC-49A8-A5FE-64E83AE200C8Q38802412-81BB0637-82AC-4CE4-98D2-36601EF3B63DQ38852355-5A503D6C-564B-468F-A13E-1D7431BCC705Q39172983-1538B2BC-EF97-4CB7-AA66-F3116EB444F6Q39312902-7DE582EC-CD4A-4C94-A1E2-86D8E4D6EBBBQ42290097-586E5BB2-D4BD-4908-9A9B-197EBB5581E9Q47107266-118BDA87-C998-4BAC-8583-B3A536904210Q47445843-08AAE1DE-75AC-4436-B63D-7E2D4106C6EDQ48110513-2F53C6C9-4874-4681-8637-069C7CF2E9E9Q48349326-94502F26-221D-442A-AA3B-D65BAF1F2DECQ50231785-2B3BD0A8-8AE7-40A4-9EAF-7091A87505B5Q50640068-2B2244C5-6CC7-4DE9-AF29-0B3CDF97438BQ52641327-1E5BC880-BB4C-4773-B621-0F7E37711C68
P2860
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@ast
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@en
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@nl
type
label
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@ast
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@en
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@nl
prefLabel
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@ast
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@en
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@nl
P2860
P3181
P1433
P1476
Everolimus plus exemestane for ...... w of subanalyses from BOLERO-2
@en
P2093
Gabriel N. Hortobagyi
P2860
P304
P3181
P356
10.1016/J.NEO.2015.01.005
P407
P5008
P577
2015-03-01T00:00:00Z